Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $13.05M rose 75.6% year over year, ahead of the +63.8% change in trailing-twelve-month research & development. Sequentially, it rose 74.7% from the prior quarter. Over 3 fiscal years it compounded at -10.3% a year.

Context

  • Research & development amounted to 11.5% of revenue in FY2025, up 2.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +75.6% holds above the trailing-twelve-month pace of +63.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$13.05M+74.7% QoQ
Last fiscal yearDec 2025
$32.51M+56.4% YoY
LTMJun 2026
$39.85M+63.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+75.6%——
1 year+56.4%——
3-year CAGR-10.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
32.51M USD
Year-over-year change
+56.4%
4-year CAGR
-10.7%

Research & Development vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 research & development of $39.85M is the lowest of the 10 companies compared; the peer median is $139.61M.
  • Its year-over-year change of +63.8% is the highest of 9, against a peer median of +35.8%.
  • Research & development amounts to 12.8% of revenue for AUPH, versus a peer median of 2390.7%.
AUPH Competitors Peer median
Research & Development for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$467.76M -32.9%+13.3%—
ALMSAlumis Inc. Common StockLTM Jun 2026$346.63M -8.7%+56.3%4685.4%
VERAVera Therapeutics, Inc.LTM Jun 2026$261.87M +51.3%+45.5%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$220.82M +62.1%+69.0%—
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M -8.4%——
EVMNEvommune, Inc.LTM Mar 2026$77M ——770.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$69.93M +20.4%+34.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M +60.6%-12.2%677.9%
ATTOAttovia Therapeutics, Inc.FY2025$54.15M +59.9%—4011.3%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$39.85M +63.8%-10.3%12.8%
Peer median (excluding AUPH) $139.61M+35.8%+40.1%2390.7%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.61M134.03M175.51M235.13M283.06M
Cost of Revenue1.09M5.66M14.15M28.25M32.67M
Gross Profit44.51M128.37M161.37M206.89M250.39M
Gross Margin97.6%95.8%91.9%88.0%88.5%
Research & Development51.14M44.99M49.64M20.79M32.51M
Selling, General & Admin171.44M196.37M195.04M172.03M101.79M
Operating Expenses225.25M239.84M253.06M211.57M145.48M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
EBITDA(177.45M)(103.65M)(63.05M)31.73M127.76M
EBITDA Margin-389.1%-77.3%-35.9%13.5%45.1%
Operating Income(180.74M)(111.47M)(91.69M)(4.69M)104.91M
Operating Margin-396.3%-83.2%-52.2%-2.0%37.1%
Interest Income529K5.12M17M16.97M13.57M
Interest Expense002.78M4.84M4.33M
Other Income / Expenses529K5.12M14.22M12.14M9.24M
Income Before Tax(180.21M)(106.35M)(77.47M)7.45M114.16M
Pre-Tax Margin-395.1%-79.3%-44.1%3.2%40.3%
Income Tax Expense760K1.83M551K1.7M(173.05M)
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (Basic)(1.40)(0.76)(0.54)0.042.14
EPS (Diluted)(1.40)(0.76)(0.54)0.042.07
Weighted Avg Shares129.37M141.92M143.24M143.06M134.37M
Weighted Avg Shares (Diluted)129.37M141.92M143.24M146.19M138.7M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.